Protagonist Therapeutics, Inc. (PTGX)

From the record

Protagonist Therapeutics, Inc.'s filings since 2017 show 2 warning events of 2 kinds: a notice about its exchange listing (8-K item 3.01, the latest 2023-07-03); an auditor change (8-K item 4.01, the latest 2020-03-18) (its current reports).

From the record

Protagonist Therapeutics, Inc.'s 9 filed years say what it did: revenue went from $20 million in fiscal 2017 to $46 million in fiscal 2025, up 10.9% a year; it rose in 4 of 8 years; the deepest fall was 99% from fiscal 2018 to fiscal 2019; net income was positive in 1 of 9 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2025-12-31, Protagonist Therapeutics, Inc.'s diluted share count grew about 9.0% a year, and dividends and buybacks returned about 0% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 39 sales (13 under scheduled 10b5-1 plans) and 0 purchases of their own stock on the open market in the year to 2026-10-02 (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Protagonist Therapeutics, Inc. lost about 21 cents for every dollar of shareholders' money. Leverage: it owed about 8 cents per dollar of assets, and net share issuance: its share count shrank 2.3% over the year (the filed statements).

From the record

Protagonist Therapeutics, Inc.'s standing among 315 graded names in its industry family: revenue of $46 million in fiscal 2025 ranks in the top 45% by size; a net margin of -282.8% ranks in the bottom 43%; revenue growth of 20.1% a year over the last 3 filed years ranks in the top 37% (its annual reports).

From the record

Protagonist Therapeutics, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Patel, Dinesh V Ph D (President and CEO, as filed), filing under that title since 2016-08-10, 10.3 years (top 16% of its family); the 8 officers and directors filing in the last fifteen months have been on the record a median of 9.5 years (top 10%); 3 officer or director changes were reported on Form 8-K since 2023-11-13, against the 8 people in charge now (top 39%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Protagonist Therapeutics, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $128 million against no long-term debt tagged leaves 19.2% of its assets as net cash, bottom 38% of its family; cash from operations less capital spending is 121.9% of revenue (top 1%); research spending of 346.2% of revenue (top 35%) (its annual report).

From the record

Protagonist Therapeutics, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 20.1% a year over the last three filed years against 10.9% over all 9, speeding up (top 19% of its family); the newest year grew -89.4% (bottom 4%); research spending grew 8.1% a year (top 42%); capital spending grew 26% a year (top 22%) (its annual reports). Protagonist Therapeutics, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

From the record

Protagonist Therapeutics, Inc.'s newest year against its own record: revenue of $46 million in fiscal 2025 came in 97.4% below the $1.8 billion its prior three years' pace pointed to (bottom 2% of its family); net income of $130 million against a prior three-year average of $23 million (bottom 3%); a net margin of a loss larger than its revenue against losses larger than its revenue before (bottom 20%) (its annual reports).